Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | AHR | P35869 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | IDH2 | P48735 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20814491 | 0.88 | LMNA (0.50) | KMT2ALMNAIDH1IDH2KDM4E | |
| SCHEMBL2490426 | 0.84 | KMT2A (0.75) | KMT2ANR1I2AHRLMNAPKM | |
| SCHEMBL15719518 | 0.81 | KCNH3 (0.39) | KMT2ANR1I2AHRLMNACYP1A2 | |
| SCHEMBL7099893 | 0.80 | KMT2A (0.69) | KMT2ANR1I2AHRLMNAPKM | |
| SCHEMBL23431616 | 0.79 | GAA (0.61) | KMT2ALMNACYP1A2CYP2C19MEN1 | |
| SCHEMBL15720210 | 0.79 | LMNA (0.43) | KMT2ALMNAIDH1IDH2KDM4E | |
| SCHEMBL20814426 | 0.78 | PDE4A (0.42) | KMT2ANR1I2AHRLMNAKDM4E | |
| SCHEMBL2356311 | 0.78 | LMNA (0.79) | KMT2ANR1I2AHRLMNAPKM | |
| Diethylamine SCHEMBL10892424 | 0.77 | KMT2A (0.66) | KMT2ANR1I2AHRLMNAPKM | |
| SCHEMBL7102854 | 0.77 | KMT2A (0.66) | KMT2ANR1I2AHRLMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS INC (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS INC (US) | 2016-09-08 | — | — | US | disclosed |
| US-9351972-B2 | Compounds as respiratory stimulants for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351972-B2 | Compounds as respiratory stimulants for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150374706-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20150374706-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9162992-B2 | Compounds and compositions for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9162992-B2 | Compounds and compositions for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140371224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2013181217-A2 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | WO | disclosed |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | MTNR1B, CHRM3, ADRA2C | KMT2A 1945/4885NR1I2 912/4885AHR 291/4885 |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | PER2, SMPD4, NDUFB5 | KMT2A 3102/4885NR1I2 1373/4885AHR 838/4885 |
| US-20140371224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | PER2, MTNR1B, NDUFB5 | KMT2A 2815/4885NR1I2 1663/4885AHR 1239/4885 |
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | P2RX5, HRH2, ADRA2C | KMT2A 1802/4885NR1I2 955/4885AHR 276/4885 |
| US-20150374706-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | PER2, SMPD4, NDUFB5 | KMT2A 3102/4885NR1I2 1373/4885AHR 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.